Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Meghan C Thompson,Matthew S Davids,Nitin Jain,Jacob D Soumerai,Praveen Ramakrishnan Geethakumari,Amy Gubits,Denice Hickman,Anders Wennborg,Eyal C Attar,Omar Abdel-Wahab,Anthony R Mato

doi:10.1182/blood-2020-139022

Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Meghan C Thompson, Matthew S Davids + Show 9 more

Open Access

https://doi.org/10.1182/blood-2020-139022

Copy DOI

Journal: Blood

Publication Date: Nov 5, 2020

Affiliation: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, The University of Texas Southwestern Medical Center, APR Technologies (Sweden)

#Chronic Lymphocytic Leukemia Pts #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Full Text